Cephalon Reaches $125M Settlement with U.S. States

Cephalon reaches its second massive settlement in just over a year for unlawfully protecting their Provigil patent.

Cephalon Settlement / Photo: statejournal.com
Cephalon Settlement / Photo: statejournal.com

According to a recent Reuters article, Cephalon will pay out a $125 million settlement to 48 states for allegedly delaying generic versions of its blockbuster sleep disorder drug, Provigil. Cephalon, now owned by Teva Pharmaceuticals, got hit with a $1.2 billion parallel settlement with the Federal Trade Commission (FTC), just over a year ago.

The FTC accused Cephalon of paying generic drug makers to drop challenges against their patent on Provigil, in a “pay-for-delay” effort to preserve their monopoly. In the end, they successfully delayed generic competition for six years by filing patent infringement lawsuits and then paying the generic drug makers to withhold entry to the market. The settlement includes $35 million to be paid out to consumers who bought Provigil when cheaper generic versions should have been available.

Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?